Treatment of Chronic Active Antibody-mediated Rejection With Bortezomib in Kidney Transplantation
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2019
Price : $35 *
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone; Immunoglobulins
- Indications Transplant rejection
- Focus Therapeutic Use
- Acronyms TRIBUTE
- 18 Oct 2019 Planned End Date changed from 1 Feb 2020 to 1 Jul 2020.
- 18 Oct 2019 Planned primary completion date changed from 1 Feb 2020 to 1 Jul 2020.
- 18 Oct 2019 Status changed from recruiting to active, no longer recruiting.